rejuvant life tabs

“The major modulators of aging remain to be discovered”

Latest articles

Paving the way to future organ factories

Extracellular matrix obtained by controlled decellularisation is used to reconstruct the liver with human-like characteristics, paving the way for transplantable livers. Researchers at the Human...

Charles Brenner: the journey from NR to Tru Niagen

Dr Charles Brenner, the developer of the intellectual property behind ChromaDex's Tru Niagen, on all things metabolism, NAD and NR clinical trials. Longevity.Technology: Following the...

Longevity investment firm announces acceleration programme

Call for future founders: longevity investment fund LongeVC announces in-house acceleration programme. LongeVC – a longevity investment group backed by an advisory board with solid...

The placenta: a limitless source of stem cells?

Part 1 of our exclusive interview with Celularity founder Dr Robert Hariri covers the discovery of placental pluripotent stem cells and the journey towards...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...
Supplement report

Editor's picks

Paving the way to future organ factories

Extracellular matrix obtained by controlled decellularisation is used to reconstruct the liver with human-like characteristics, paving the way for transplantable livers. Researchers at the Human...

Charles Brenner: the journey from NR to Tru Niagen

Dr Charles Brenner, the developer of the intellectual property behind ChromaDex's Tru Niagen, on all things metabolism, NAD and NR clinical trials. Longevity.Technology: Following the...

Longevity investment firm announces acceleration programme

Call for future founders: longevity investment fund LongeVC announces in-house acceleration programme. LongeVC – a longevity investment group backed by an advisory board with solid...
Rejuvant

Buck Institute start-up Gerostate Alpha reveals work to develop small molecule drugs that simultaneously target multiple pathways of aging.

Deep in the labs of the world-renowned Buck Institute for Research on Aging, a company is growing. Founded by a team of senior Buck scientists, Gerostate Alpha is steadily working on the development of new drugs that target aging.

The three founding PhDs behind the company, Simon Melov, Gordon Lithgow and Mark Lucanic, bring more than 50 years’ combined experience in age-related science. Together, they are focused on developing new drugs to increase health span and extend lifespan by treating aging itself.

Longevity.Technology: While the company’s web site states that Gerostate Alpha is “dedicated to treating aging and age-related disease,” it doesn’t say much more than that. So when we had the opportunity to speak with co-founders Melov and Lucanic, we jumped at the chance to learn more about this mysterious company.

While many companies in Longevity are focused on addressing one or more of the hallmarks, or pillars, of aging, the founders of Gerostate Alpha always saw things a little differently.

“People take the hallmarks of aging as a launching off point, thinking that if they can forestall a particular pillar, let’s say inflammation, then they’ll get beneficial outcomes – but this is a biased approach,” says Melov. “We’ve always been interested in looking at aging mechanisms in an unbiased way, whether through genetic interventions, or pharmacological interventions, we’re not beholden to a particular mechanism, per se.”

Having talked about forming a company for years, the three founders were convinced after Y Combinator’s Sam Altman presented at the Buck in 2018 about the need to see more quality initiatives coming out of the biotech space regarding aging.

 


 

 

“You often hear people say they ‘target aging’ but you have to ask what does that mean… ?”

 

 


 

“Having been involved in the basic biology of aging and trying to understand the degenerative changes of aging from a mechanistic perspective for many years, that resonated with us,” says Melov. “And so we put together a proposal focused around some of the ideas, particularly with regard to an unbiased way to identify molecules which might retard the aging process. We pitched it to Y Combinator, they really liked us and gave us a million dollars to start the company. It was certainly the fastest million we ever made in our careers!”

And so Gerostate Alpha was born, and the team proceeded to develop its idea to screen molecules for aging, in as unbiased a way as possible. The company name, by the way, refers to someone’s “gerostate” as being the physiological outcomes of their aging process, with “alpha” indicating the best possible outcome of that process.

Elevant

“You often hear people say they ‘target aging’ but you have to ask what does that mean – does it mean targeting a pillar of aging: senescence, inflammation, mitochondrial dysfunction?” asks Melov. “That’s not targeting aging – that’s targeting something other people have said is linked to aging processes. Everyone is very familiar now with using those terms, but it roots you in the idea that we understand what aging is, and we don’t think we do. We believe that these pillars of aging are just one of many, and we think that the major modulators of aging remain to be discovered.”

 


 

“The platform is geared towards identifying interventions that attenuate or halt multiple aging indications simultaneously.”

 

 


 

Gerostate Alpha has constructed a platform to try and identify new aging pathways, which can be manipulated to improve healthspan, function, and perhaps even increase lifespan.

“The processes of aging start early, and we’re interested in identifying those processes, and tweaking them through small molecules so that we can stop this decline or attenuate the slope and reap the benefits in terms of your individual physiologies,” says Melov. “The platform is geared towards identifying interventions that attenuate or halt multiple aging indications simultaneously. And you need the tools to do that in a preclinical model, which is tractable.”

“But we don’t want to come across as though we’re starry-eyed and using a start-up strategy to pursue intellectual questions,” he adds. “We’re targeting six major areas of unmet medical need: the CNS, muscle decline, pulmonary decline, skeletal decline, cardiovascular, and metabolic. Many of them don’t have any medicines at all, and diseases are associated with each of those in which there’s a tremendous need for developing therapeutics. And so, although we’re targeting aging in a very genuine, robust and rigorous way, we’re also targeting it through the prism of commercialization.”

Longevity.Technology: Read the second part of our interview with Gerostate Alpha, covering the details of its discovery platform, roadmap and fundraising plans.

1 COMMENT

Comments are closed.

Danny Sullivan
Contributing Editor Danny has worked in technology communications for more than 15 years, spanning Europe and North America. From bionics and lasers to software and pharmaceuticals – and everything in between – he’s covered it all. Danny has wide experience of technology publishing and technical writing and has specific interest in the transfer from idea to market.
Rejuvant

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...
Supplement report

Related articles

Paving the way to future organ factories

Extracellular matrix obtained by controlled decellularisation is used to reconstruct the liver with human-like characteristics, paving the way for transplantable livers. Researchers at the Human...

The placenta: a limitless source of stem cells?

Part 1 of our exclusive interview with Celularity founder Dr Robert Hariri covers the discovery of placental pluripotent stem cells and the journey towards...

Insulin – predictor of longevity

Body weight stands for far more than simple aesthetics – it is key for longevity. From a single cell to a fully functioning human adult,...

Juvenescence debuts ketosis longevity supplement drink

Biotech Juvenescence's new product Metabolic Switch is a drink that supports healthy aging and a healthy metabolism by generating a state of ketosis. It's been...

Targeting neurodegeneration with $82m Series A

Alchemab raises £60 million to advance novel platform for identifying disease-modifying antibody therapeutics for neurodegeneration, cancer and more. UK-based biotech Alchemab Therapeutics has secured a...
Supps report ad middle